Track topics on Twitter Track topics that are important to you
DelveInsight's, Metastatic Hormone Refractory Prostate CancerPipeline Insights, 2017, report provides comprehensive insights of the ongoing therapeutic research and development across Metastatic Hormone Refractory Prostate Cancer. The report provides a complete understanding of the pipeline activities covering all clinical, preclinical and discovery stage products. A comparative pipeline therapeutics assessment of Metastatic Hormone Refractory Prostate Cancer by development stage, therapy type, route of administration and molecule type is also covered in the report. It also has a special feature on the inactive pipeline products in this area.
The report is built using data and information sourced from proprietary databases, primary and secondary research and inhouse analysis by DelveInsights team of industry experts.
Secondary sources information and data has been collected from various printable and nonprintable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.
Scope of the report
The report provides a snapshot of the pipeline development for the Metastatic Hormone Refractory Prostate Cancer
The report covers pipeline activity across the complete product development cycle i.e. clinical, preclinical and discovery stages for the Metastatic Hormone Refractory Prostate Cancer
The report provides pipeline product profiles which includes product description, developmental activities, licensors collaborators and chemical information
Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Metastatic Hormone Refractory Prostate Cancer
The report also covers the dormant and discontinued pipeline projects related to the Metastatic Hormone Refractory Prostate Cancer
Reasons to Buy
Establish comprehensive understanding of the pipeline activity across this Metastatic Hormone Refractory Prostate Cancer to formulate effective RD strategies
Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Metastatic Hormone Refractory Prostate Cancer therapeutics
Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress
Endocrine disorders are grouped into two categories: hormone imbalance - when a gland produces too much or too little of an endocrine hormone development of lesions (such as nodules or tumors) in the endocrine system, which may or may not affect...
Prostate cancer (cancer de prostata) Prostate cancer (cancer de prostata) is a form of cancer that develops in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, there are cases of aggressive prostat...
Diabetes Diabetes Endocrine Obesity Oxycontin Renal Disease Thyroid Disorders Endocrinology is the study of the endocrine glands and the hormones that they secrete (Oxford Medical Dictionary). There are several groups of h...